ReViral
ExitedReViral is a biotechnology company that develops and offers antiviral therapies for patients.
ReViral has raised €37M across 1 funding round from 1 investor, most recently a Series C round in Aug 2020. Based in Stevenage, UK; founded 2011; active in Healthtech. Acquired by Pfizer in 2022. Data as of 28 Oct 2026.
Total raised
€37M
€37,322,928
Funding rounds
1
Investors
1
distinct backers
Active since
2020-08
latest 2020-08
Funding by year
EUR raised per yearReViral — funding by year — interactive chart.
Data table
| ReViral — funding by year | |
|---|---|
| 2020 | €37M |
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-08-27 | Series C | €37M | CR-CP Life Science Fund | View deal → |
Exit
Type
acquisition
Date
Apr 2022
Value
€483M
Acquiror
Pfizer (United States of America)
Investors
1Related news
- Pfizer to Buy ReViral, For Up To $525Mfinsmes.com · 2022-04
- finsmes.com
Similar companies
same sector or countryGlobal coverage: FundingData